# China NMPA Drug Inspection - Hebei Union Pharmaceutical CO., LTD. - Morinda officinalis

Source: https://www.globalkeysolutions.net/records/china_drug_inspection/hebei-union-pharmaceutical-co-ltd/de3674be-c02d-4945-a0b5-983899fb6030/
Source feed: China

> China NMPA drug inspection for Hebei Union Pharmaceutical CO., LTD. published May 04, 2018. Drug: Morinda officinalis. The Heilongjiang Provincial Food and Drug Administration issued an announcement on May 4, 2018, revealing significant co

---

## Details

- Record Type: CHINA_DRUG_INSPECTION
- Title: Announcement from the Heilongjiang Provincial Food and Drug Administration regarding 18 batches of substandard drugs (preparations) and traditional Chinese medicine decoction pieces (No. 4, 2018)
- Company Name: Hebei Union Pharmaceutical CO., LTD.
- Publication Date: 2018-05-04
- Drug Name: Morinda officinalis
- Inspection Finding: The random inspection failed, and the non-compliant items involved inspection, content determination, properties, identification, and extractives.
- Action Taken: Relevant food and drug regulatory authorities have taken control measures such as sealing and seizing, requiring the sampled units to suspend the sale and use of this batch of products and to rectify the situation; and in accordance with the relevant provisions of the "Drug Administration Law of the People's Republic of China," have initiated investigations into the illegal sale of substandard drugs and have ordered the public disclosure of the results within a specified period.
- Summary: The Heilongjiang Provincial Food and Drug Administration issued an announcement on May 4, 2018, revealing significant compliance failures identified through sampling inspections. Six testing institutions found 18 batches of drugs, preparations, and traditional Chinese medicine decoction pieces to be substandard. These products originated from 13 manufacturers, including Jilin Mizhikang Pharmaceutical Co., Ltd., Shanghai Pujin Linzhou Pharmaceutical Co., Ltd., and Hebei Zhijia Pharmaceutical Co., Ltd. Main violations encompassed failures in inspection parameters, content determination, product properties, identification tests, and extractives. In response, regulatory bodies implemented immediate control measures, such as sealing and seizing affected batches and suspending their sale and use. Operating under Articles 73, 74, and 75 of the *Drug Administration Law of the People's Republic of China*, the Provincial Bureau mandated local food and drug administrations to investigate these illegal acts. They are required to publicly disclose investigation results and imposed penalties on the involved enterprises within three months, and subsequently report findings to the Provincial Bureau. This action highlights a firm commitment to upholding drug quality and public health standards.

Company: https://www.globalkeysolutions.net/companies/hebei-union-pharmaceutical-co-ltd/c2692895-8526-45c4-8536-1f1030df3fac/